MedTrace Logo

Clinical Trials of IBI3035 in Healthy Subjects

NCT07591519 · Status: NOT_YET_RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 144

Last updated 2026-05-15

No results posted yet for this study

Summary

This study is a Phase I clinical trial that uses positive glucose clamping technology to evaluate the pharmacokinetic (PK) and pharmacodynamic (PD) bioequivalence of IBI3035 with insulin injection (Awiqli?) after a single administration in healthy male subjects

Conditions

  • Healthy Person

Interventions

BIOLOGICAL

IBI3035

IBI3035 administered subcutaneously(SC)

BIOLOGICAL

Insulin icodec Injection

Insulin icodec Injection administered subcutaneously(SC)

Sponsors & Collaborators

  • Innovent Biologics (Suzhou) Co. Ltd.

    lead INDUSTRY

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
CROSSOVER

Eligibility

Min Age
18 Years
Max Age
45 Years
Sex
MALE
Healthy Volunteers
Yes

Timeline & Regulatory

Start
2026-05-08
Primary Completion
2027-07-30
Completion
2027-08-31

Countries

  • China

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07591519 on ClinicalTrials.gov